Abstract

A miniaturized biosensor for carbamazepine (CBZ) detection and quantification was designed, implemented and fabricated. The 1×1 mm2 CMOS chip was packaged and coupled with a 3-electrode electrochemical cell. A complete characterization of the sensor was conducted via two steps: 1) Molecular imprinting of PEDOT polymer sites by cyclic voltammetry (CV) on glassy carbon electrode (GCE) surfaces; and 2) Quantification of CBZ solutions through both CV, and a current peak detection circuitry. The proposed biosensor offered high-selectivity and high-sensitivity to CBZ molecules. Scanning electron microscopy (SEM) was utilized to validate the synthesis of the PEDOT chains. CBZ removal from the imprinted polymer was conducted through soaking the modified GCEs in acetonitrile (ACN). Extraction was then confirmed by ultraviolet-visible (UV-vis) spectroscopy and CV analyzing data from pre- and post-template extraction. Furthermore, in order to characterize the electrodes' response to CBZ levels in phosphate buffered solution (PBS) with [Fe(CN)6]3-/4- as a redox pair/mediator, CV and peak detection was conducted resulting in redox peak currents vs. CBZ concentration graphs. The limits of detection (LOD) and quantification (LOQ) were calculated to be 2.04 and 6.2 μg/mL respectively. Finally, selectivity towards CBZ was validated by studying the effect of valproic acid (VPA) and phenytoin (PHT) on the biosensor's performance. The proposed biosensor is highly sensitive and selective to CBZ molecules, simple to construct and easy to operate.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call